N-(4-bromo-3-methylphenyl)-3-oxobutanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-bromo-3-methylphenyl)-3-oxobutanamide
• 化学式: C₁₁H₁₂BrNO₂
• 分子量: 270.126
• InChiKey: YJXDHZLYBMNSPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-bromo-3-methylphenyl)-3-oxobutanamide 、 氰乙酰胺 在 吗啉 、 1,2,3,4,5,6,7,8-八硫杂环辛烷 作用下， 以 乙醇 为溶剂， 以85%的产率得到5-amino-N2-(4-bromo-3-methylphenyl)-3-methylthiophene-2,4-dicarboxamide
  参考文献：
  名称：

  5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors

  摘要：

  Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 mu M, CC50 > 100 mu M = 25%) and 19k (EC50 = 0.31 mu M, CC50 > 100 mu M, F = 46%), displayed overall lead profiles superior to reported CAEs 7-10 used in our studies. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.047
• 作为产物：
  描述：

  4-溴-3-甲基苯胺 、 乙酰乙酸乙酯 在 potassium tert-butylate 作用下， 以 甲苯 为溶剂， 反应 6.0h， 生成 N-(4-bromo-3-methylphenyl)-3-oxobutanamide
  参考文献：
  名称：

  5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors

  摘要：

  Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 mu M, CC50 > 100 mu M = 25%) and 19k (EC50 = 0.31 mu M, CC50 > 100 mu M, F = 46%), displayed overall lead profiles superior to reported CAEs 7-10 used in our studies. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.047

文献信息

• Water – the best solvent for DMAP-mediated dual cyclization towards metal-free first synthesis of fully substituted phthalimides
  作者：Subhasis Samai、Debasish Ghosh、Uttam K. Das、Sanghamitra Atta、Saikat K. Manna、Dilip K. Maiti

  DOI：10.1039/c6gc00367b

  日期：——

  DMAP in water is exploited for a [2 + 2 + 2] and [3 + 2] cascade dual annulation for the first synthesis of fully-substituted phthalimides.

  在水中利用DMAP进行了[2 + 2 + 2]和[3 + 2]级联双环化反应，首次合成了全取代邻苯二甲酰亚胺。
• QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS
  申请人：UCL BUSINESS PLC

  公开号：US20170291875A1

  公开（公告）日：2017-10-12

  The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:
• 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors
  作者：Jing Tang、Andrew D. Huber、Dallas L. Pineda、Kelsey N. Boschert、Jennifer J. Wolf、Jayakanth Kankanala、Jiashu Xie、Stefan G. Sarafianos、Zhengqiang Wang

  DOI：10.1016/j.ejmech.2018.12.047

  日期：2019.2

  Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 mu M, CC50 > 100 mu M = 25%) and 19k (EC50 = 0.31 mu M, CC50 > 100 mu M, F = 46%), displayed overall lead profiles superior to reported CAEs 7-10 used in our studies. (C) 2018 Elsevier Masson SAS. All rights reserved.